FibroGen Stock Forecast, Price & News

+0.06 (+0.28 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $21.12
50-Day Range
MA: $29.60
52-Week Range
Now: $21.12
Volume1.39 million shs
Average Volume1.49 million shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FGEN
Year FoundedN/A



Sales & Book Value

Annual Sales$256.58 million
Book Value$6.14 per share


Net Income$-76,970,000.00
Net Margins-191.78%


Market Cap$1.94 billion
Next Earnings Date5/6/2021 (Estimated)


Fibrogen Investor Alert: Class Action Lawsuit Filed
April 22, 2021 |
FibroGen (NASDAQ:FGEN) Shares Up 5.3%
April 20, 2021 |
See More Headlines


Overall MarketRank

1.77 out of 5 stars

Medical Sector

177th out of 2,024 stocks

Pharmaceutical Preparations Industry

76th out of 771 stocks

Analyst Opinion: 4.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.06 (+0.28 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

Is FibroGen a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FibroGen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View analyst ratings for FibroGen
or view top-rated stocks.

What stocks does MarketBeat like better than FibroGen?

Wall Street analysts have given FibroGen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but FibroGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for FibroGen

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Sunday, February, 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.35. The biopharmaceutical company had revenue of $65 million for the quarter, compared to the consensus estimate of $100.82 million. FibroGen had a negative net margin of 191.78% and a negative trailing twelve-month return on equity of 48.19%. The company's quarterly revenue was up 712.5% compared to the same quarter last year. During the same period last year, the company posted ($1.12) EPS.
View FibroGen's earnings history

How has FibroGen's stock been impacted by Coronavirus?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FGEN shares have decreased by 40.3% and is now trading at $21.12.
View which stocks have been most impacted by COVID-19

What price target have analysts set for FGEN?

8 equities research analysts have issued 1 year price objectives for FibroGen's shares. Their forecasts range from $29.00 to $58.00. On average, they anticipate FibroGen's stock price to reach $45.83 in the next year. This suggests a possible upside of 117.0% from the stock's current price.
View analysts' price targets for FibroGen
or view top-rated stocks among Wall Street analysts.

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. James A. Schoeneck, Chairman (Age 63, Pay $751.63k)
  • Mr. Pat Cotroneo, Chief Financial Officer (Age 57, Pay $773.57k)
  • Dr. Elias Kouchakji, Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance (Age 65, Pay $863.19k)
  • Ms. Christine L. Chung, Sr. VP of China Operations (Age 53, Pay $701.09k)
  • Mr. Enrique A. Conterno, CEO & Director (Age 54)
  • Dr. Barry A. Berkowitz, Founder
  • Dr. Michael J. Martinelli, Sr. VP of Technical Devel.
  • Dr. Percy Carter M.B.A., Ph.D., Chief Scientific Officer
  • Ms. Karen L. Bergman, VP of Investor Relations & Corp. Communications
  • Mr. Michael D. Lowenstein J.D., Ph.D., Chief Legal Officer

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Polianta Ltd (0.04%), EFG Asset Management Americas Corp. (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold FibroGen company stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen
or view top insider-selling stocks.

Which institutional investors are buying FibroGen stock?

FGEN stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and EFG Asset Management Americas Corp..
View insider buying and selling activity for FibroGen
or or view top insider-buying stocks.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $21.12.

How much money does FibroGen make?

FibroGen has a market capitalization of $1.94 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does FibroGen have?

FibroGen employs 599 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is

Where are FibroGen's headquarters?

FibroGen is headquartered at 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

This page was last updated on 4/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.